Last reviewed · How we verify

ADT for 9 months and ARTA for 6 months

Tata Memorial Centre · Phase 2 active Small molecule

ADT for 9 months and ARTA for 6 months is a Androgen receptor inhibitor Small molecule drug developed by Tata Memorial Centre. It is currently in Phase 2 development for Prostate cancer, Metastatic prostate cancer.

Androgen deprivation therapy (ADT) involves blocking the production of androgens, such as testosterone, which fuel the growth of prostate cancer cells. Androgen receptor signaling inhibitor (ARTA) works by blocking the androgen receptor, preventing cancer cells from receiving the signals they need to grow and multiply.

Androgen deprivation therapy (ADT) involves blocking the production of androgens, such as testosterone, which fuel the growth of prostate cancer cells. Androgen receptor signaling inhibitor (ARTA) works by blocking the androgen receptor, preventing cancer cells from receiving the signals they need to grow and multiply. Used for Prostate cancer, Metastatic prostate cancer.

At a glance

Generic nameADT for 9 months and ARTA for 6 months
SponsorTata Memorial Centre
Drug classAndrogen receptor inhibitor
TargetAndrogen receptor
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

ADT is typically used to treat hormone-sensitive cancers, such as prostate cancer, by reducing the levels of androgens in the body. ARTA, on the other hand, targets the androgen receptor itself, preventing cancer cells from responding to androgens. This dual approach can be effective in treating hormone-sensitive cancers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ADT for 9 months and ARTA for 6 months

What is ADT for 9 months and ARTA for 6 months?

ADT for 9 months and ARTA for 6 months is a Androgen receptor inhibitor drug developed by Tata Memorial Centre, indicated for Prostate cancer, Metastatic prostate cancer.

How does ADT for 9 months and ARTA for 6 months work?

Androgen deprivation therapy (ADT) involves blocking the production of androgens, such as testosterone, which fuel the growth of prostate cancer cells. Androgen receptor signaling inhibitor (ARTA) works by blocking the androgen receptor, preventing cancer cells from receiving the signals they need to grow and multiply.

What is ADT for 9 months and ARTA for 6 months used for?

ADT for 9 months and ARTA for 6 months is indicated for Prostate cancer, Metastatic prostate cancer.

Who makes ADT for 9 months and ARTA for 6 months?

ADT for 9 months and ARTA for 6 months is developed by Tata Memorial Centre (see full Tata Memorial Centre pipeline at /company/tata-memorial-centre).

What drug class is ADT for 9 months and ARTA for 6 months in?

ADT for 9 months and ARTA for 6 months belongs to the Androgen receptor inhibitor class. See all Androgen receptor inhibitor drugs at /class/androgen-receptor-inhibitor.

What development phase is ADT for 9 months and ARTA for 6 months in?

ADT for 9 months and ARTA for 6 months is in Phase 2.

What are the side effects of ADT for 9 months and ARTA for 6 months?

Common side effects of ADT for 9 months and ARTA for 6 months include Hot flashes, Fatigue, Muscle weakness, Bone loss, Infertility.

What does ADT for 9 months and ARTA for 6 months target?

ADT for 9 months and ARTA for 6 months targets Androgen receptor and is a Androgen receptor inhibitor.

Related